Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes

Biochemical Journal

Volumn 367, Issue 3, 2002, Pages 913-920

  Gault, Victor A ^a   Flatt, Peter R ^a   Bailey, Clifford J ^a   Harriott, Patrick ^a   Greer, Brett ^a   Mooney, Mark H ^a   O'Harte, Finbarr P M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Dipeptidyl peptidase IV (DPP IV); GIP analogues; Insulin secretion; Obese diabetic (ob ob) mice

Indexed keywords

BIOLOGICAL ORGANS; CELLS; CLONING; DISEASES; ENZYMES; GLUCOSE; HORMONES; METABOLISM; PLASMAS; POLYPEPTIDES;

IN VITRO POTENCY;

BIOCHEMISTRY;

CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE DERIVATIVE; GLUCOSE DEPENDENT INSULINOTRPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; INSULIN; N 9 FLUORENYLMETHOXYCARBONYL GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; N PALMITATE GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CELLS, CULTURED; CRICETINAE; CYCLIC AMP; DIABETES COMPLICATIONS; DIABETES MELLITUS; GASTRIC INHIBITORY POLYPEPTIDE; HYPOGLYCEMIA; INSULIN; MICE; OBESITY; PROTEIN ISOFORMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TYROSINE;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0036844953     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20020319     Document Type: Article

References (49)

1. Creutzfeldt, W. (2001) The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109, 288-303
2. Nauck, M. A., Bartels, E., Ørskov, C., Ebert, R. and Creutzfeldt, W. (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76, 912-917
3. Deacon, C. F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. and Holst, J. J. (1998) Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41, 271-278
4. Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. H. and Demuth, H.-U. (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47, 1253-1258
5. Holst, J. J. (1999) Glucagon-like peptide-1, a gastrointestinal hormone with pharmaceutical potential. Curr. Med. Chem. 6, 1005-1017
6. O'Harte, F. P. M., Mooney, M. H. and Flatt, P. R. (1999) N-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycaemic activity. Diabetes 48, 758-765
7. Pauly, R. P., Demuth, H.-U., Rosche, F., Schmidt, J., White, H., Lynn, F., McIntosh, C. H. S. and Pederson, R. A. (1999) Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide. Metab. Clin. Exp. 48, 385-389
8. O'Harte, F. P. M., Mooney, M. H., Kelly, C. M. N. and Flatt, P. R. (2000) Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J. Endocrinol. 165, 639-648
9. Mentlein, R., Gallwitz, B. and Schmidt, W. E. (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214. 829-835
10. Kieffer, T. J., McIntosh, C. H. S. and Pederson, R. A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596
11. Pauly, R. P., Rosches, F., Wermann, M., McIntosh, C. H. S., Pederson, R. A. and Demuth, H.-U. (1996) Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. J. Biol. Chem. 271, 23222-23229
12. Schmidt, W. E., Siegel, E. G., Kümmel, H., Gallwitz, B. and Creutzfeldt, W. (1987) Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. Endocrinology 120, 835-837
13. Gelling, R. W., Coy, D. H., Pederson, R. A., Wheeler, M. B., Hinke, S., Kwan, T. and McIntosh, C. H. S. (1997) GIP 6-30 amide contains the high affinity binding region of GIP and is a potent inhibitor of GIP 1-42 action in vitro. Regul. Pept. 69, 151-154
14. O'Dorisio, T. M., Sirinek, K. R., Mazzaferri, E. L. and Cataland, S. (1976) Renal effects on serum gastric inhibitory polypeptide (GIP). Metab. Clin. Exp. 26, 651-656
15. Ruiz-Grande, C., Alarcón, C., Alcántara, A., Castiila, C., López Novoa, J. M., Villanueva Peñacarillo, M. L. and Valverde, I. (1993) Renal catabolism of truncated glucagon-like peptide 1. Horm. Metab. Res. 25, 612-616
16. Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M. and Holst, J. J. (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 271, E458-E464
17. Sirinek, K. R., O'Dorisio, T. M., Gaskill, H. V. and Levine, B. A. (1984) Chronic renal failure: Effect of hemodialysis on gastrointestinal hormones. Am. J. Surg. 148, 732-735
18. Jorde, R., Burhol, P. G., Gunnes, P. and Schulz, T. B. (1981) Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. Scand. J. Gastroenterol. 16, 469-471
19. Deacon, C. F., Danielsen, P., Klarskov, L., Olesen, M. and Holst, J. J. (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycaemic effects in anesthetized pigs. Diabetes 50, 1588-1597
20. Ritzel, U., Leonhardt, U., Ottleben, M., Rühmann, A., Eckart, K, Speiss, J. and Ramadori, G. (1998) A synthetic glucagon-like peptide-1 analogue with improved plasma stability. J. Endocrinol. 159, 93-102
21. Burcelin, R., Dolci, W. and Thorens, B. (1999) Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metab. Clin. Exp. 48, 252-258
22. Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M. and Agersø, H (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664-1669
23. Kurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Riebel, U. and Markussen, J. (1996) Albumin-binding and time action of acylated insulins in various species. J. Pharm. Sci. 85, 304-308
24. Markussen, J., Havelund, S., Kurtzhals, P., Andersen, A. S., Halstøm, J., Hasselager, E., Larsen, U. D., Ribel, U., Schaffer, L., Vad, K. and Jonassen, I. (1996) Soluble, fatty-acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281-288
25. Myers, S. R., Yakubumadus, F. E., Johnson, W. T., Baker, J. E., Cusick, T. S., Williams, V. K., Tinsly, F. C., Kriauciunas, A., Manetta, J. and Chen, V. J. (1997) Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 46, 637-642
26. Fields, G. B. and Noble, R. L. (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161-214
27. Gremlich, S., Porret, A., Hani, E. H., Cherif, D., Vionnet, N., Froguel, P. and Thorens, B. (1995) Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44, 1202-1208
28. Widmann, C., Bürki, E., Dorci, W. and Thorens, B. (1993) Signal transduction by the cloned glucagon-like peptide-1 receptor: Comparison with signalling by the endogenous receptors of β cell lines. Mol. Pharmacol. 45, 1029-1035
29. McClenaghan, N. H., Barnett, C. R., Ah-Sing, E., Abdel-Wahab, Y. H. A., O'Harte, F. P. M., Yoon, T.-W., Swanston-Flatt, S. K. and Flatt, P. R. (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45, 1132-1140
30. Flatt, P. R. and Bailey, C. J. (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577
31. Bailey, C. J. and Flatt, P. R. (1982) Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obesity 6, 11-21
32. Stevens, J. F. (1971) Determination of glucose by automatic analyser. Clin. Chim. Acta 32, 199-201
33. Burington, R. S. (1973) Handbook of Mathematical Tables and Formulas, McGraw-Hill, New York
34. Tseng, C.-C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B. and Wolfe, M. M. (1996) Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide. J. Clin. Invest. 98, 2440-2445
35. Tseng, C.-C., Zhang, X.-Y. and Wolfe, M. M. (1999) Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am. J. Physiol. 276, E1049-E1054
36. Eckel, R. H., Fujimoto, W. J. and Brunzell, J. D. (1978) Gastric inhibitory polypeptide enhances lipoprotein lipase activity in cultured preadipocytes. Diabetes 28, 1141-1142
37. Elahi, D., Meneilly, G. S., Minaker, K. L., Rowe, J. W. and Andersen, D. K. (1986) Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. In Proceedings of Sixth International Conference on Gastrointestinal Hormones, p. 18, National Research Council of Canadian Research Journals, Ottawa
38. Hartmann, H., Ebert, R. and Creutzfeldt, W. (1986) Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver. Diabetologia 29, 112-114
39. Ebert, R., Nauck, M. and Creutzfeldt, W. (1991) Effect of exogenous or endogenous gastric inhibitory polypeptide on plasma triglyceride responses in rats. Horm. Metab. Res. 23, 517-521
40. Oben, J., Morgan, L. M., Fletcher, J. and Marks, V. (1991) Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1-(7-36) amide on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 130, 267-272
41. Rachman, J. and Turner, R. C. (1995) Drugs on the horizon for treatment of type 2 diabetes. Diabetic Med. 12, 467-478
42. Jones, I. R., Owens, D. R., Luzio, S. Williams, S. and Hayes, T. M. (1989) The glucose-dependent insulinotropic polypeptide response to oral glucose and mixed meals is decreased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32, 668-677
43. Fukase, N., Igarashi, M., Takahashi, H., Manaka, H., Yamatan, K., Daimon, M., Tominga, M. and Sasaki, H. (1993) Hypersecretion of truncatee glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabetic Med. 10, 44-49
44. Vaag, A. A., Hoist, J. J., Volund, A. and Beck-Neitsen, H. B. (1996) Gut incretin hormones in identical twins discordant for non-insulin dependent diabetes mellitus (NIDDM): Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur. J. Endocrinol. 135, 425-432
45. Ahren, B., Larsson, H. and Hoist, J. J. (1997) Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal woman with impaired glucose tolerance. Eur. J. Endocrinol. 137, 127-131
46. O'Harte, F. P. M., Abdel-Wahab, Y. H. A., Conlon, J. M. and Flatt, P. R. (1998) Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim. Biophys. Acta 1425, 319-327
47. Flatt, P. R., Bailey, C. J., Kwasowski, P., Page, T. and Marks, V. (1984) Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J. Endocrinol. 101, 249-256
48. O'Harte, F. P. M., Gray, A. M. and Flatt, P. R. (1998) Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J. Endocrinol. 156, 237-243
49. 4 GIP: Physiology and pathology. Biochem. Soc. Trans. 24, 585-591